Literature DB >> 11668479

TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus.

E M Maggio1, E Stekelenburg, A Van den Berg, S Poppema.   

Abstract

Reed-Sternberg (RS) cells, the neoplastic cells of Hodgkin lymphoma (HL) have clonal immunoglobulin gene rearrangements. The presence of somatic mutations suggests a germinal center origin, whereas the presence of crippling mutations suggests rescue of RS precursors from apoptosis by a transforming event. Epstein-Barr virus (EBV), which can be detected in 30-50% of HL cases, probably plays a role in this transforming event. The frequent presence of p53 protein expression in RS cells also suggests a role of the TP53 gene in this escape from apoptosis. Although mutations of the TP53 gene occur infrequently in RS cells, it has been suggested that in EBV-negative cases this gene mutation may be fundamental for the inhibition of apoptosis. In this study, we tested the hypothesis that there is an inverse correlation between the presence of TP53 gene mutations and the presence of EBV. In 21 of 67 cases EBV encoded small RNA (EBER)1-2 mRNAs were detected. Immunostaining for p53 protein revealed positivity in all 67 cases with variable percentages of positive cells and staining intensity. Screening for mutations in exons 5, 6, 7 and 8 of the TP53 gene in single RS cells obtained by laser microdissection from 26 HL specimens and 4 HL-derived cell lines revealed mutations in 2 of 15 EBV-positive cases and in 1 of 11 EBV-negative cases. Our results confirm the presence of infrequent (11.5%) TP53 gene mutations in HL and suggest that mutations of the TP53 gene are not correlated to the absence of EBV. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11668479     DOI: 10.1002/ijc.1438

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma.

Authors:  Ewerton M Maggio; Anke Van Den Berg; Debora de Jong; Arjan Diepstra; Sibrand Poppema
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

2.  Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Authors:  Enrico Tiacci; Erik Ladewig; Gianluca Schiavoni; Alex Penson; Elisabetta Fortini; Valentina Pettirossi; Yuchun Wang; Ariele Rosseto; Alessandra Venanzi; Sofija Vlasevska; Roberta Pacini; Simonetta Piattoni; Alessia Tabarrini; Alessandra Pucciarini; Barbara Bigerna; Alessia Santi; Alessandro M Gianni; Simonetta Viviani; Antonello Cabras; Stefano Ascani; Barbara Crescenzi; Cristina Mecucci; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  Blood       Date:  2018-04-12       Impact factor: 22.113

Review 3.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

4.  Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.

Authors:  Emmanuelle Boulanger; Agnès Marchio; Saw-See Hong; Pascal Pineau
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

5.  Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study.

Authors:  Nagehan O Barisik; Suheyla Bozkurt; Mahmut Gumus; Isik Kaygusuz; Nimet Karadayi; Emine Bas; Mahmut Bayik; Tulay Tecimer
Journal:  Diagn Pathol       Date:  2010-03-26       Impact factor: 2.644

6.  Epstein-Barr virus infection correlates with the expression of COX-2, p16(INK4A) and p53 in classic Hodgkin lymphoma.

Authors:  Suhail Al-Salam; Aktham Awwad; Manjusha Sudhadevi; Sayel Daoud; Nico J D Nagelkerke; Antonio Castella; S M Chong; Mouied Alashari
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

7.  Role of immunoexpression of nitric oxide synthases by Hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical Hodgkin lymphoma.

Authors:  Antônio H J F M Campos; Vera L Aldred; Karina C B Ribeiro; José Vassallo; Fernando A Soares
Journal:  Mol Cell Biochem       Date:  2008-10-02       Impact factor: 3.396

8.  Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q.

Authors:  Ronald Boonstra; Alice Koning; Mirjam Mastik; Anke van den Berg; Sibrand Poppema
Journal:  Virchows Arch       Date:  2003-06-12       Impact factor: 4.064

9.  Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups.

Authors:  Kevin Y Urayama; Ruth F Jarrett; Henrik Hjalgrim; Arjan Diepstra; Yoichiro Kamatani; Amelie Chabrier; Valerie Gaborieau; Anne Boland; Alexandra Nieters; Nikolaus Becker; Lenka Foretova; Yolanda Benavente; Marc Maynadié; Anthony Staines; Lesley Shield; Annette Lake; Dorothy Montgomery; Malcolm Taylor; Karin Ekström Smedby; Rose-Marie Amini; Hans-Olov Adami; Bengt Glimelius; Bjarke Feenstra; Ilja M Nolte; Lydia Visser; Gustaaf W van Imhoff; Tracy Lightfoot; Pierluigi Cocco; Lambertus Kiemeney; Sita H Vermeulen; Ivana Holcatova; Lars Vatten; Gary J Macfarlane; Peter Thomson; David I Conway; Simone Benhamou; Antonio Agudo; Claire M Healy; Kim Overvad; Anne Tjønneland; Beatrice Melin; Federico Canzian; Kay-Tee Khaw; Ruth C Travis; Petra H M Peeters; Carlos A González; José Ramón Quirós; María-José Sánchez; José María Huerta; Eva Ardanaz; Miren Dorronsoro; Françoise Clavel-Chapelon; H Bas Bueno-de-Mesquita; Elio Riboli; Eve Roman; Paolo Boffetta; Silvia de Sanjosé; Diana Zelenika; Mads Melbye; Anke van den Berg; Mark Lathrop; Paul Brennan; James D McKay
Journal:  J Natl Cancer Inst       Date:  2012-01-27       Impact factor: 13.506

10.  Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population.

Authors:  David Dynnes Ørsted; Stig Egil Bojesen; Anne Tybjaerg-Hansen; Børge Grønne Nordestgaard
Journal:  J Exp Med       Date:  2007-05-29       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.